Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.



<ul>
<li>UBS analyst Weston Bloomer upgraded Arthur J. Gallagher &amp; Co. (NYSE:AJG) from Neutral to Buy and lowers the price target from $283 to $250. Arthur J. Gallagher shares closed at $212.52 on Monday. See how other analysts view this stock.</li>



<li>Sidoti &amp; Co. analyst Steve Ferazani upgraded Brady Corp (NYSE:BRC) from Neutral to Buy and announced a $103 price target. Brady shares closed at $75.28 on Monday. See how other analysts view this stock.</li>



<li>GLJ Research analyst Gordon L. Johnson upgraded Cleveland-Cliffs Inc (NYSE:CLF) from Sell to Hold and raised the price target from $9.03 to $15.01. Cleveland-Cliffs shares closed at $12.68 on Monday. See how other analysts view this stock.</li>



<li>JP Morgan analyst Ella Smith upgraded PAR Technology Corporation (NYSE:PAR) from Underweight to Neutral and raised the price target from $12 to $16. PAR Technology shares closed at $13.28 on Monday. See how other analysts view this stock.</li>



<li>Barclays analyst Luke Sergott upgraded West Pharmaceutical Services, Inc. (NYSE:WST) from Equal-Weight to Overweight and raised the price target from $310 to $400. West Pharmaceutical shares closed at $319.75 on Monday. See how other analysts view this stock.</li>
</ul>



Considering buying BRC stock? Here’s what analysts think: 



<figure class="wp-block-image size-large is-resized"></figure>



Photo via Shutterstock

Wall Street analysts upgraded five stocks on Tuesday. UBS upgraded Arthur J. Gallagher (AJG) to Buy with a $250 target. Sidoti & Co. upgraded Brady Corp (BRC) to Buy with a $103 target. GLJ Research upgraded Cleveland-Cliffs (CLF) to Hold with a $15.01 target. JP Morgan upgraded PAR Technology (PAR) to Neutral with a $16 target. Barclays upgraded West Pharmaceutical Services (WST) to Overweight with a $400 target.

benzinga_article

West Pharmaceutical

This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday